Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker ABBV · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | A Study to Assess the Adverse Events and How Oral ABBV-1606 Moves Through the Body of Healthy Adult… NCT07935564 · Healthy Volunteer ABBV-1606, Placebo | ABBV AbbVie | Phase 1 | Not yet recruiting | 40 | Jul 2027 | Registry ↗ |
| Nov 13, 2026 | Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adul… NCT07680686 · Healthy Volunteer Ubrogepant, Ubrogepant | ABBV AbbVie | Phase 1 | Completed was active, not recruiting | 52 | Oct 16, 2026 | Registry ↗ |
| Nov 13, 2026 | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and A… NCT05889182 · Hidradenitis Suppurativa Upadacitinib, Placebo | ABBV AbbVie | Phase 3 | Active, not recruiting | 1,328 | Aug 2028 | Registry ↗ |
| Nov 13, 2026 | Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or… NCT03850782 · Open-Angle Glaucoma, Ocular Hypertension Bimatoprost (SR) | ABBV AbbVie | Phase 3 | Completed | 515 | Aug 8, 2025 | Registry ↗ |
| Nov 12, 2026 | A Study to Assess Targeted Therapies for Treatment of Adults With Moderate to Severe Psoriasis NCT07933536 · Moderate to Severe Psoriasis Risankizumab, ABBV-295 | ABBV AbbVie | Phase 2 | Not yet recruiting | 105 | Dec 2028 | Registry ↗ |
| Nov 12, 2026 | M4 Receptor PET Radioligand Validation Study in Healthy Adults NCT07933497 · Healthy Volunteers [11C]ABBV-112i | ABBV AbbVie | Early phase 1 | Not yet recruiting | 6 | Feb 2027 | Registry ↗ |
| Nov 12, 2026 | A Study to Evaluate the Safety and Efficacy (How Well the Study Treatment Works) of ABBV-2294 in Ad… NCT07933211 · Systemic Sclerosis ABBV-722, Upadacitinib | ABBV AbbVie | Phase 2/3 | Not yet recruiting | 580 | Jun 2035 | Registry ↗ |
| Nov 12, 2026 | An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Ad… NCT06023030 · Crohn's Disease | ABBV AbbVie | — | Completed was recruiting | 253 | Sep 11, 2026 | Registry ↗ |
| Nov 10, 2026 | Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid Arthr… NCT07904754 · Rheumatoid Arthritis ABBV-722, Upadacitinib | ABBV AbbVie | Phase 2 | Not yet recruiting | 250 | Jul 2029 | Registry ↗ |
| Nov 10, 2026 | Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participan… NCT07227896 · Parkinson's Disease | ABBV AbbVie | — | Recruiting | 100 | Oct 2027 | Registry ↗ |
| Nov 10, 2026 | A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Partic… NCT05650632 · Multiple Myeloma Etentamig (ABBV-383) | ABBV AbbVie | Phase 1 | Recruiting | 250 | Aug 2029 | Registry ↗ |
| Nov 9, 2026 | A Study to Assess How Intravenous and Subcutaneous Administrations of Trosunilimab Move Through the… NCT07925983 · Healthy Volunteer Trosunilimab, Trosunilimab | ABBV AbbVie | Phase 1 | Recruiting | 60 | May 2027 | Registry ↗ |
| Nov 9, 2026 | A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of… NCT07514260 · Healthy Volunteer ABBV-295, Placebo for ABBV-295 | ABBV AbbVie | Phase 1 | Active, not recruiting | 24 | Dec 2026 | Registry ↗ |
| Nov 9, 2026 | Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis NCT06865105 · Psoriatic Arthritis Lutikizumab, Risankizumab | ABBV AbbVie | Phase 2 | Recruiting | 300 | Aug 2029 | Registry ↗ |
| Nov 9, 2026 | An Observational Study to Assess Ubrogepant Tablets and Atogepant Tablets to Treat Migraine in Adul… NCT05827887 · Migraine | ABBV AbbVie | — | Completed | 226 | Jan 28, 2026 | Registry ↗ |
| Nov 6, 2026 | A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Bo… NCT06032546 · Human Immuno-deficiency Virus (HIV) Disease Budigalimab, Placebo for Budigalimab | ABBV AbbVie | Phase 2 | Terminated | 163 | Sep 22, 2025 | Registry ↗ |
| Nov 6, 2026 | Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Change in Disease Activi… NCT05959083 · Atopic Dermatitis (AD) | ABBV AbbVie | — | Completed | 200 | May 7, 2026 | Registry ↗ |
| Nov 6, 2026 | Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With… NCT05296447 · Diabetic Retinopathy, DR Standard of Care, Aflibercept | ABBV AbbVie | Phase 2 | Active, not recruiting was enrolling by invitation | 103 | Jun 2031 | Registry ↗ |
| Nov 5, 2026 | A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and Onabotulinum… NCT07871513 · Upper Facial Lines, Glabellar Lines TrenibotulinumtoxinE and OnabotulinumtoxinA, Placebo | ABBV AbbVie | Phase 2 | Recruiting | 300 | Jun 2028 | Registry ↗ |
| Nov 5, 2026 | A Study to Evaluate How Multiple Doses of Itraconazole Interacts With Nacresertib in Healthy Adult… NCT07649954 · Healthy Volunteer Nacresertib, Itraconazole | ABBV AbbVie | Phase 1 | Completed was active, not recruiting | 12 | Oct 5, 2026 | Registry ↗ |
| Nov 5, 2026 | A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult… NCT07291232 · Obesity ABBV-295, Placebo | ABBV AbbVie | Phase 1 | Active, not recruiting was recruiting | 80 | Apr 2027 | Registry ↗ |
| Nov 4, 2026 | Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through t… NCT05753501 · Hematologic Cancer ABBV-101 | ABBV AbbVie | Phase 1 | Active, not recruiting | 135 | Mar 2031 | Registry ↗ |
| Nov 3, 2026 | Expanded Access to Tavapadon NCT07158827 · Parkinson Disease Tavapadon | ABBV AbbVie | — | No longer available was available | — | — | Registry ↗ |
| Nov 3, 2026 | Expanded Access to Venetoclax NCT03123029 · Relapsed/Refractory Lymphoid Malignancies, Relapsed/Refract… Venetoclax | ABBV AbbVie | — | Available | — | — | Registry ↗ |
| Nov 2, 2026 | A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adul… NCT07756580 · Glabellar Lines AGN-151586, BOTOX | ABBV AbbVie | Phase 1 | Active, not recruiting was recruiting | 143 | Feb 2027 | Registry ↗ |
| Nov 2, 2026 | A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerat… NCT01848561 · Ulcerative Colitis (UC) | ABBV AbbVie | — | Completed was active, not recruiting | 8,250 | Sep 30, 2026 | Registry ↗ |
| Oct 29, 2026 | A Single Ascending Dose, and Food Effect Study of ABBV-7828 in Healthy Adults NCT07856706 · Healthy Subjects ABBV-7828, Placebo for ABBV-7828 | ABBV AbbVie | Phase 1 | Recruiting was not yet recruiting | 60 | May 2027 | Registry ↗ |
| Oct 29, 2026 | Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic… NCT07592273 · Diabetic Retinopathy Surabgene Lomparvovec, Sham | ABBV AbbVie | Phase 2/3 | Recruiting | 576 | Jun 2028 | Registry ↗ |
| Oct 29, 2026 | Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Pre… NCT07007065 · Neovascular Age-related Macular Degeneration Surabgene Lomparvovec (ABBV-RGX-314), Ranibizumab Control | ABBV AbbVie | Phase 3 | Recruiting | 561 | Mar 2033 | Registry ↗ |
| Oct 29, 2026 | A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Com… NCT04928846 · Non Small Cell Lung Cancer, c-MET Telisotuzumab Vedotin, Docetaxel | ABBV AbbVie | Phase 3 | Recruiting | 768 | Dec 2028 | Registry ↗ |
| Oct 28, 2026 | A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participant… NCT06602479 · Migraine MEDI0618, Placebo | ABBV AbbVie | Phase 2 | Active, not recruiting | 309 | Feb 2027 | Registry ↗ |
| Oct 28, 2026 | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including… NCT03671148 · Psoriatic Arthritis (PsA) Placebo, Risankizumab | ABBV AbbVie | Phase 3 | Active, not recruiting | 444 | Jun 22, 2020 | Registry ↗ |
| Oct 27, 2026 | A Study to Learn How Effective, Safe, and Tolerable Upadacitinib is for Young Participants With Non… NCT07896434 · Non-Segmental Vitiligo Upadacitinib, Placebo for Upadacitinib | ABBV AbbVie | Phase 3 | Not yet recruiting | 154 | Aug 2032 | Registry ↗ |
| Oct 27, 2026 | Real-World Study of Mirvetuximab Soravtansine in Adult Participants With Platinum-Resistant FRα-Pos… NCT07896421 · Platinum-Resistant FRα-Positive Ovarian Cancer, Platinum-Re… | ABBV AbbVie | — | Recruiting | 500 | Apr 2030 | Registry ↗ |
| Oct 27, 2026 | A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alo… NCT07772492 · Severe Alopecia Areata Upadacitinib, Placebo | ABBV AbbVie | Phase 3 | Recruiting | 300 | Mar 2032 | Registry ↗ |
| Oct 27, 2026 | Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidit… NCT07752979 · Obesity, Overweight ABBV-295, Placebo | ABBV AbbVie | Phase 2 | Recruiting | 360 | Mar 2028 | Registry ↗ |
| Oct 27, 2026 | A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) T… NCT07744126 · Head and Neck Squamous Cell Carcinoma Telisotuzumab Adizutecan, Pembrolizumab | ABBV AbbVie | Phase 2 | Recruiting | 150 | Oct 2029 | Registry ↗ |
| Oct 27, 2026 | Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Act… NCT07697456 · Crohn's Disease, Ulcerative Colitis Risankizumab, Trosunilimab | ABBV AbbVie | Phase 2 | Recruiting | 2,000 | Oct 2031 | Registry ↗ |
| Oct 27, 2026 | Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participant… NCT07673107 · Upper Limb Essential Tremor AGN-151607-DP, Placebo for AGN-151607-DP | ABBV AbbVie | Phase 2 | Recruiting | 94 | Nov 2028 | Registry ↗ |
| Oct 27, 2026 | A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous… NCT07155174 · Small Cell Lung Cancer ABBV-706, Atezolizumab | ABBV AbbVie | Phase 2 | Recruiting | 180 | Apr 2029 | Registry ↗ |
| Oct 27, 2026 | A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis NCT07071519 · Ulcerative Colitis Risankizumab, Risankizumab | ABBV AbbVie | Phase 3 | Recruiting | 120 | Jul 2034 | Registry ↗ |
| Oct 27, 2026 | A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Com… NCT06953960 · Multiple Myeloma Surzetoclax, Daratumumab | ABBV AbbVie | Phase 1/2 | Recruiting | 325 | Dec 2030 | Registry ↗ |
| Oct 27, 2026 | A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizuteca… NCT06820463 · Metastatic Colorectal Cancer Telisotuzumab Adizutecan, Fluorouracil | ABBV AbbVie | Phase 2 | Recruiting | 390 | Mar 2028 | Registry ↗ |
| Oct 27, 2026 | Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combi… NCT06772623 · Non Small Cell Lung Carcinoma, c-MET Telisotuzumab Adizutecan, Budigalimab | ABBV AbbVie | Phase 1/2 | Recruiting | 252 | Nov 2027 | Registry ↗ |
| Oct 26, 2026 | A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Com… NCT07895056 · Extensive Stage-Small Cell Lung Cancer ABBV-706, Tarlatamab | ABBV AbbVie | Phase 2 | Not yet recruiting | 80 | Aug 2031 | Registry ↗ |
| Oct 26, 2026 | A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Com… NCT07895043 · Extensive Stage-Small Cell Lung Cancer (ES-SCLC) Alveltamig, Atezolizumab | ABBV AbbVie | Phase 2 | Not yet recruiting | 80 | Dec 2031 | Registry ↗ |
| Oct 22, 2026 | A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sun… NCT07581002 · Acute Myeloid Leukemia Pivekimab Sunirine, Venetoclax | ABBV AbbVie | Phase 2/3 | Recruiting | 660 | Jun 2032 | Registry ↗ |
| Oct 22, 2026 | Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Mod… NCT06764706 · Ulcerative Colitis | ABBV AbbVie | — | Recruiting | 200 | Jul 2028 | Registry ↗ |
| Oct 22, 2026 | A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399… NCT06568939 · Non-Small Cell Lung Cancer, c-MET Telisotuzumab Vedotin | ABBV AbbVie | Phase 2 | Recruiting | 150 | Feb 2028 | Registry ↗ |
| Oct 21, 2026 | A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination Wit… NCT06487559 · Hepatocellular Carcinoma (HCC) Livmoniplimab, Budigalimab | ABBV AbbVie | Phase 1 | Terminated | 3 | Sep 18, 2026 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:34 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances